机器人对比胸腹腔镜食管切除术治疗食管癌的随机临床试验
这项3期随机临床试验在4个高容量中心纳入218例可切除的食管或食管胃交界腺癌患者,比较机器人辅助微创食管切除术(RAMIE)与传统微创食管切除术(MIE)。结论支持机器人食管切除术作为食管或食管胃交界腺癌的标准术式。
要点
- RAMIE可获得更彻底的淋巴结清扫且安全性相当,支持其作为标准术式。
核心结论
- 机器人食管切除术相比传统微创食管切除术提供了更彻底的淋巴结清扫,且手术安全性结果相当。
- 结果支持将机器人食管切除术作为食管或食管胃交界腺癌的标准 approach。
研究设计与样本
- 3期随机临床试验,2021年1月至2025年3月在德国美因茨、荷兰阿姆斯特丹、瑞士苏黎世和德国科隆的4个高容量三级转诊中心开展。
- 纳入可切除的食管或食管胃交界腺癌,分期为cT1-4a、cN0-3、cM0,允许原发手术和多模式治疗设置。
- 共218例患者初始随机分组,其中202例完成研究并接受经胸食管切除术,随访长达5年。
- 参与者按1:1随机分配至RAMIE或传统MIE,主要终点为切除淋巴结数量,按改良意向性治疗分析。
主要发现
- 202例接受经胸食管切除术的患者中(平均[SD]年龄64.8[10.1]岁;181例[89.6%]男性),101例接受RAMIE,101例接受MIE。
- 管腔R0切除率RAMIE组为99.0%,MIE组为97.0%。
- 1年生存率两组无差异。
临床怎么用
- 对于可切除的食管或食管胃交界腺癌,机器人食管切除术可作为标准术式以获得更彻底的淋巴结清扫。
- 机器人手术并未增加术后并发症或90天死亡风险,安全性与传统微创手术相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The optimal surgical approach for oncological thoracoabdominal esophagectomy for adenocarcinoma is unclear. Robot-assisted minimally invasive esophagectomy (RAMIE) may facilitate a more extensive lymphadenectomy compared with conventional minimally invasive esophagectomy (MIE), which is crucial to achieve a favorable oncological outcome. OBJECTIVE: To determine whether RAMIE results in a higher yield of resected lymph nodes compared with conventional MIE in patients undergoing surgery for esophageal or esophagogastric junction adenocarcinoma. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 3 randomized clinical trial conducted between January 2021 and March 2025 at 4 high-volume tertiary referral centers in Mainz, Germany; Amsterdam, the Netherlands; Zurich, Switzerland; and Cologne, Germany. Patients with resectable adenocarcinoma of the esophagus or esophagogastric junction staged as cT1-4a, cN0-3, and cM0 were included. Both primary surgery and multimodal treatment settings were eligible. A total of 218 patients were initially randomized, 202 of whom completed the study and underwent transthoracic esophagectomy with follow-up up to 5 years. INTERVENTIONS: Participants were randomly assigned (1:1) to RAMIE or conventional MIE. MAIN OUTCOMES AND MEASURES: The primary end point was the number of resected lymph nodes, planned a priori and analyzed on a modified intention-to-treat basis. Secondary measures included luminal R0 resection rates, postoperative complication rates, 90-day mortality, and 1-year survival. RESULTS: Between 2021 and 2025, 218 patients were included in the study, 202 of whom (mean [SD] age, 64.8 [10.1] years; 181 [89.6%] male) underwent transthoracic esophagectomy (101 RAMIE and 101 MIE). The median number of resected lymph nodes was significantly higher in RAMIE compared to MIE (36 vs 32; P = .005). Luminal R0 resection was 99.0% with RAMIE and 97.0% with MIE. Rates of postoperative complications were similar between groups; 90-day mortality was 1.0% in the RAMIE group and 3.0% in the MIE group (P = .62). There was no difference in survival after 1 year. CONCLUSIONS AND RELEVANCE: In this study, robotic esophagectomy provided a more radical lymphadenectomy compared to conventional minimally invasive esophagectomy with equal results for surgical safety. These results support the use of robotic esophagectomy as a standard approach for adenocarcinoma of the esophagus or esophagogastric junction. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04306458.
引用
- Berlth F, Gisbertz SS, Tagkalos E, et al. Robotic vs Thoracolaparoscopic Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial. JAMA Surg. 2026. PMID: 42814447. doi:10.1001/jamasurg.2026.4478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。